Skip to main content
An official website of the United States government

Funding Opportunities

The NCI Division of Cancer Prevention funds new research in cancer prevention, detection, screening, interception, and symptom management. We also fund programs to train people for careers in research. Explore current open funding opportunities here and streamline your search by using keyword or type of funding.

Please check the “Other Notices” tab on the NIH Guide for Grants and Contracts to see updates to NIH policies that ensure alignment with the Administration’s priorities.

Notice of Funding Opportunities

Title Announcement Number Activity Code Clinical Trials Status Expiration Date Program Official
Assay Validation of High Quality Markers for Clinical Studies in Cancer PAR-25-074 (UH2/UH3 Clinical Trial Not Allowed) UH2, UH3 Clinical Trial Not Allowed 10/14/2026 Sudhir Srivastava, Ph.D., M.P.H.
Assay Validation of High Quality Markers for Clinical Studies in Cancer PAR-25-075 (UH3 Clinical Trials Not Allowed) UH3 10/14/2026 Sudhir Srivastava, Ph.D., M.P.H.
Cancer Prevention and Control Clinical Trials Grant Program PAR-25-167 (R01 Clinical Trial Required) R01 Clinical Trial Required 01/07/2027 Goli Samimi, Ph.D., M.P.H.
Cancer Prevention and Control Clinical Trials Planning Grant Program PAR-25-104 (R34 Clinical Trials Optional) R34 10/25/2027 Goli Samimi, Ph.D., M.P.H.
Cancer Prevention and Control Clinical Trials Planning Grant Program PAR-25-103 (U34 Clinical Trials Optional) U34 10/25/2027 Brandy Heckman-Stoddard, Ph.D., M.P.H.
Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies PAR-25-145 (R01 Clinical Trial Optional) R01 Clinical Trial Optional 01/07/2028 Rachel Altshuler, Ph.D.
Enhancing Mechanistic Research on Precision Probiotic Therapies PAR-25-211 (R61/R33 Clinical Trial Optional) R61, R33 Clinical Trial Optional 06/02/2027 Gabriela Riscuta, M.D., CNS
HEAL Initiative: Studies to Enable Analgesic Discovery RFA-NS-25-023 (R61/R33 - Clinical Trial Not Allowed) R61, R33 Clinical Trial Not Allowed 02/20/2027 Rachel Altshuler, Ph.D.
Mechanisms that Impact Cancer Risk after Bariatric Surgery PAR-25-043 (R01 Clinical Trial Optional) R01 Clinical Trial Optional 01/07/2028 Edward Sauter, M.D., Ph.D.
Mechanisms that Impact Cancer Risk after Bariatric Surgery PAR-25-044 (R21 Clinical Trial Not Allowed) R21 Clinical Trial Not Allowed 01/07/2028 Edward Sauter, M.D., Ph.D.